We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Gastroenterology

Journal Scan / Research · June 30, 2020

Novel Antisense Inhibition of Diacylglycerol O-Acyltransferase 2 for Treatment of NALFD

The Lancet Gastroenterology & Hepatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Gastroenterology & Hepatology
Novel Antisense Inhibition of Diacylglycerol O-Acyltransferase 2 for Treatment of Non-Alcoholic Fatty Liver Disease: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Trial
Lancet Gastroenterol Hepatol 2020 Jun 15;[EPub Ahead of Print], R Loomba, E Morgan, L Watts, S Xia, LA Hannan, RS Geary, BF Baker, S Bhanot

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading